Vertex Pharmaceuticals Incorporated

VRTX

NASDAQBiotechnology🇺🇸North America

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 8, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
VX-121/TEZ/D-IVA	Phase 3	Cystic Fibrosis	-
Lumacaftor	Phase 3	Cystic Fibrosis	-
ELX/TEZ/IVA	Phase 3	Cystic Fibrosis	-
VX-661 plus ivacaftor combination	Phase 3	Cystic Fibrosis	-
IVA	Phase 3	Cystic Fibrosis	-
Placebo	Phase 3	Cystic Fibrosis, Homozygous for the F508del CFTR Mutation	-
Tezacaftor/Ivacaftor	Phase 3	Cystic Fibrosis	-
LUM/IVA	Phase 3	Cystic Fibrosis	-
Ivacaftor	Phase 3	Cystic Fibrosis	-
VX-445/TEZ/IVA	Phase 3	Cystic Fibrosis	-
VX-880	Phase 3	Type 1 Diabetes	OrphanFast TrackBreakthrough
ribavirin	Phase 3	Hepatitis C	-
TEZ	Phase 3	Cystic Fibrosis	-
TEZ/IVA	Phase 3	Cystic Fibrosis	-
Biological/Vaccine	Phase 3	Type 1 Diabetes	-
Casgevy Exagamglogene Autotemcel	Phase 3	Sickle Cell Disease	OrphanFast TrackBreakthrough
VX-147	Phase 3	Proteinuric Kidney Disease	-
Lumacaftor Plus Ivacaftor Combination	Phase 3	Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	-
Suzetrigine	Phase 3	Pain	-
VX-548	Phase 3	Acute Pain	Fast Track
Povetacicept	Phase 3	Primary Membranous Nephropathy	-
CTX001	Phase 3	Beta-Thalassemia	-
VX-661/Ivacaftor	Phase 3	Cystic Fibrosis	-
Placebo (matched to SUZ)	Phase 3	Diabetic Peripheral Neuropathic Pain	-
VX-993	Phase 2	Acute Pain	-
Placebo (matched to VX-548)	Phase 2	Acute Pain	-
Telaprevir	Phase 2	Hepatitis C	-
Tezacaftor/Ivacaftor matching placebo	Phase 2	Cystic Fibrosis	-
VX-152	Phase 2	Cystic Fibrosis	-
VX-809	Phase 2	Cystic Fibrosis	-
VX-765	Phase 2	Partial Epilepsy	-
VX-659	Phase 2	Cystic Fibrosis	-
VX-770	Phase 2	Cystic Fibrosis	-
Pregabalin	Phase 2	Diabetic Peripheral Neuropathic Pain	-
VX-661	Phase 2	Cystic Fibrosis	-
Cethrin	Phase 2	Spinal Cord Injury	-
VX-950	Phase 2	Hepatitis C	-
Daclatasvir	Phase 2	Chronic Hepatitis C	-
VX-445	Phase 2	Cystic Fibrosis	-
VX-150	Phase 2	Osteoarthritis	-
VX-135	Phase 2	Chronic Hepatitis C	-
VX-561	Phase 2	Cystic Fibrosis	-
HB/APAP	Phase 2	Acute Pain	-
VX-670	Phase 2	Myotonic Dystrophy Type 1 (DM1)	-
Ivacaftor 25 mg/75 mg	Phase 2	Cystic Fibrosis	-
VX-702	Phase 2	Rheumatoid Arthritis	-
VX-864	Phase 2	Alpha1-Antitrypsin Deficiency	-
Inaxaplin	Phase 2	Proteinuric Kidney Disease	-
VCH-759 (BCH-27759)	Phase 2	Hepatitis C, Chronic	-
VX-121	Phase 2	Cystic Fibrosis	-
VX-509	Phase 2	Rheumatoid Arthritis	-
Placebo (matched to VX-121 suspension)	Phase 2	Cystic Fibrosis	-
telaprevir or matching placebo	Phase 2	Hepatitis C	-
VX-787	Phase 2	Influenza Virus	-
Pegylated Interferon Alfa 2a	Phase 2	Chronic Hepatitis C	-
VX-222	Phase 2	Chronic Hepatitis C Virus	-

Catalyst Timeline

9 upcoming, 0 past

⭐Phase 3Next

CTX001 Phase 3 Results Expected

Dec 8, 2025CTX001

Primary completion for CTX001 trial (NCT03655678) in Beta-Thalassemia

Source

Phase 2

VX-993 Phase 2 Results Expected

Apr 30, 2026VX-993

Primary completion for VX-993 trial (NCT06619860) in Diabetic Peripheral Neuropathic Pain

Source

⭐Phase 3

ELX/TEZ/IVA Phase 3 Results Expected

Apr 30, 2026ELX/TEZ/IVA

Primary completion for ELX/TEZ/IVA trial (NCT05153317) in Cystic Fibrosis

Source

Phase 2

Pregabalin Phase 2 Results Expected

Apr 30, 2026Pregabalin

Primary completion for Pregabalin trial (NCT06619860) in Diabetic Peripheral Neuropathic Pain

Source

⭐Phase 3

IVA Phase 3 Results Expected

Apr 30, 2026IVA

Primary completion for IVA trial (NCT05153317) in Cystic Fibrosis

Source

⭐Phase 3

VX-147 Phase 3 Results Expected

May 31, 2026VX-147

Primary completion for VX-147 trial (NCT05312879) in Proteinuric Kidney Disease

Source

⭐Phase 3

CTX001 Phase 3 Results Expected

May 31, 2026CTX001

Primary completion for CTX001 trial (NCT05329649) in Sickle Cell Disease

Source

⭐Phase 3

Biological/Vaccine Phase 3 Results Expected

Sep 17, 2026Biological/Vaccine

Primary completion for Biological/Vaccine trial (NCT06832410) in Type 1 Diabetes

Source

⭐Phase 3

VX-121/TEZ/D-IVA Phase 3 Results Expected

Oct 30, 2026VX-121/TEZ/D-IVA

Primary completion for VX-121/TEZ/D-IVA trial (NCT05444257) in Cystic Fibrosis

Source

Regulatory Approvals

VRTX News

Vertex Pharmaceuticals Incorporated

VRTX

NASDAQBiotechnology🇺🇸North America

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 8, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
VX-121/TEZ/D-IVA	Phase 3	Cystic Fibrosis	-
Lumacaftor	Phase 3	Cystic Fibrosis	-
ELX/TEZ/IVA	Phase 3	Cystic Fibrosis	-
VX-661 plus ivacaftor combination	Phase 3	Cystic Fibrosis	-
IVA	Phase 3	Cystic Fibrosis	-
Placebo	Phase 3	Cystic Fibrosis, Homozygous for the F508del CFTR Mutation	-
Tezacaftor/Ivacaftor	Phase 3	Cystic Fibrosis	-
LUM/IVA	Phase 3	Cystic Fibrosis	-
Ivacaftor	Phase 3	Cystic Fibrosis	-
VX-445/TEZ/IVA	Phase 3	Cystic Fibrosis	-
VX-880	Phase 3	Type 1 Diabetes	OrphanFast TrackBreakthrough
ribavirin	Phase 3	Hepatitis C	-
TEZ	Phase 3	Cystic Fibrosis	-
TEZ/IVA	Phase 3	Cystic Fibrosis	-
Biological/Vaccine	Phase 3	Type 1 Diabetes	-
Casgevy Exagamglogene Autotemcel	Phase 3	Sickle Cell Disease	OrphanFast TrackBreakthrough
VX-147	Phase 3	Proteinuric Kidney Disease	-
Lumacaftor Plus Ivacaftor Combination	Phase 3	Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	-
Suzetrigine	Phase 3	Pain	-
VX-548	Phase 3	Acute Pain	Fast Track
Povetacicept	Phase 3	Primary Membranous Nephropathy	-
CTX001	Phase 3	Beta-Thalassemia	-
VX-661/Ivacaftor	Phase 3	Cystic Fibrosis	-
Placebo (matched to SUZ)	Phase 3	Diabetic Peripheral Neuropathic Pain	-
VX-993	Phase 2	Acute Pain	-
Placebo (matched to VX-548)	Phase 2	Acute Pain	-
Telaprevir	Phase 2	Hepatitis C	-
Tezacaftor/Ivacaftor matching placebo	Phase 2	Cystic Fibrosis	-
VX-152	Phase 2	Cystic Fibrosis	-
VX-809	Phase 2	Cystic Fibrosis	-
VX-765	Phase 2	Partial Epilepsy	-
VX-659	Phase 2	Cystic Fibrosis	-
VX-770	Phase 2	Cystic Fibrosis	-
Pregabalin	Phase 2	Diabetic Peripheral Neuropathic Pain	-
VX-661	Phase 2	Cystic Fibrosis	-
Cethrin	Phase 2	Spinal Cord Injury	-
VX-950	Phase 2	Hepatitis C	-
Daclatasvir	Phase 2	Chronic Hepatitis C	-
VX-445	Phase 2	Cystic Fibrosis	-
VX-150	Phase 2	Osteoarthritis	-
VX-135	Phase 2	Chronic Hepatitis C	-
VX-561	Phase 2	Cystic Fibrosis	-
HB/APAP	Phase 2	Acute Pain	-
VX-670	Phase 2	Myotonic Dystrophy Type 1 (DM1)	-
Ivacaftor 25 mg/75 mg	Phase 2	Cystic Fibrosis	-
VX-702	Phase 2	Rheumatoid Arthritis	-
VX-864	Phase 2	Alpha1-Antitrypsin Deficiency	-
Inaxaplin	Phase 2	Proteinuric Kidney Disease	-
VCH-759 (BCH-27759)	Phase 2	Hepatitis C, Chronic	-
VX-121	Phase 2	Cystic Fibrosis	-
VX-509	Phase 2	Rheumatoid Arthritis	-
Placebo (matched to VX-121 suspension)	Phase 2	Cystic Fibrosis	-
telaprevir or matching placebo	Phase 2	Hepatitis C	-
VX-787	Phase 2	Influenza Virus	-
Pegylated Interferon Alfa 2a	Phase 2	Chronic Hepatitis C	-
VX-222	Phase 2	Chronic Hepatitis C Virus	-